Karius, Inc.

About Karius, Inc.

Karius aims to advance infectious disease diagnostics by leveraging clinical metagenomics and AI. Their vision is to create a world where every patient receives a clear and timely diagnosis for infections impacting human health.

Products & Services

Karius Spectrum:A solution for detecting microbial cell-free DNA to identify pathogens causing infections.

Karius Focus | BAL:A focused diagnostic tool for detecting pathogens, likely related to bronchoalveolar lavage (BAL) samples.

Specialties

Clinical Metagenomics Infectious Disease Diagnostics Microbial Cell-Free DNA Detection AI and Machine Learning in Genomics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2024-05-02 FD: 2024-05-02	11 investors

Series C Latest

2024-05-02

$100.0M

11 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alec Ford

Chief Executive Officer

T

Tim Blauwkamp

Chief Scientific Officer

S

Sivan Bercovici

Chief Technology and Business Officer

B

Bradley Perkins

Chief Medical Officer

S

Steve Malaska

Chief Legal Officer

B

Bill Quirk

Chief Financial Officer

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

Karius, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised